<DOC>
	<DOCNO>NCT00047827</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness micafungin combination AmBisome first-line therapy treatment invasive aspergillosis .</brief_summary>
	<brief_title>Trial Micafungin ( FK463 ) Combination With Liposomal Amphotericin B ( AmBisome ) Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Inclusion Criteria Have prove probable systemic infection Aspergillus species receive 96 hour prior therapeutic dos systemic antifungal therapy Exclusion Criteria Has abnormal liver test parameter , e.g. , AST ALT &gt; 10 time upper limit normal Has allergic bronchopulmonary aspergillosis , aspergillomas , sinus aspergillosis external otitis evidence tissue invasion Has life expectancy less five day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Aspergillus</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>Anti-Fungal</keyword>
	<keyword>AmBisome</keyword>
	<keyword>Micafungin</keyword>
</DOC>